Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Adamis Pharmaceuticl (ADMP)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 109,242
  • Shares Outstanding, K 47,291
  • Annual Sales, $ 15,090 K
  • Annual Income, $ -39,010 K
  • 60-Month Beta 1.45
  • Price/Sales 7.49
  • Price/Cash Flow N/A
  • Price/Book 2.42

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.15
  • Number of Estimates 2
  • High Estimate -0.13
  • Low Estimate -0.17
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +34.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.17 +6.72%
on 03/19/19
3.29 -29.48%
on 02/26/19
-0.81 (-25.88%)
since 02/20/19
3-Month
2.06 +12.62%
on 12/28/18
3.29 -29.48%
on 02/26/19
-0.07 (-2.93%)
since 12/20/18
52-Week
2.01 +15.42%
on 12/20/18
5.10 -54.51%
on 07/02/18
-1.11 (-32.26%)
since 03/20/18

Most Recent Stories

More News
Adamis Pharmaceuticals Announces 2018 Financial Results and Provides Business Update

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced financial results for the year ended December 31, 2018 and provided a business update.

ADMP : 2.32 (+0.43%)
Adamis Pharmaceuticals Announces FDA Acceptance for Review of the New Drug Application of Its Higher Dose Naloxone Injection Product Candidate

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that theU.S. Food and Drug Administration("FDA") has accepted for review the company's New Drug Application ("NDA") for its...

ADMP : 2.32 (+0.43%)
Adamis Pharmaceuticals (ADMP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Adamis (ADMP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ADMP : 2.32 (+0.43%)
Adamis Provides Regulatory Update on Sublingual Tadalafil

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that it has received a Refusal to File letter from the United States Food and Drug Administration (FDA) regarding its New Drug Application...

ADMP : 2.32 (+0.43%)
Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) ("Adamis") announced today that the article entitled "Higher doses of naloxone are needed in the synthetic opioid era" has been published in the peer reviewed...

ADMP : 2.32 (+0.43%)
Adamis' Commercial Partner Launches SYMJEPI(TM) (epinephrine) in the US

Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced that its marketing and commercial partner, Sandoz Inc. (Sandoz), a Novartis division, has launched SYMJEPI(TM) (epinephrine) 0.3 mg Injection...

ADMP : 2.32 (+0.43%)
Detailed Research: Economic Perspectives on Biohaven Pharmaceutical Holding, Air Transport Services Group, Pattern Energy Group, First Solar, Limelight Networks, and Adamis Pharmaceuticals -- What Drives Growth in Today's Competitive Landscape

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Biohaven Pharmaceutical...

BHVN : 49.28 (-1.54%)
PEGI : 21.82 (+0.23%)
FSLR : 55.65 (+0.36%)
ADMP : 2.32 (+0.43%)
ATSG : 20.87 (+3.27%)
LLNW : 3.05 (+0.33%)
4 Pharma Stocks Gaining Speed on Monday (12/31/18)

CORAL GABLES, FL/ ACCESSWIRE / December 31,2018 / With the new year only moments away, companies in the are working hard to create new methods and approaches for treating patients with innumerable diseases...

RAD : 0.70 (unch)
ADMP : 2.32 (+0.43%)
SGYP : 0.03 (-52.00%)
Adamis Pharmaceuticals (ADMP) Jumps: Stock Rises 5.3%

Adamis Pharmaceuticals (ADMP) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

MLNT : 4.36 (-7.04%)
ADMP : 2.32 (+0.43%)
Implied Volatility Surging for Adamis Pharmaceuticals (ADMP) Stock Options

Adamis Pharmaceuticals (ADMP) needs investors to pay close attention to the stock based on moves in the options market lately.

ADMP : 2.32 (+0.43%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ADMP with:

Business Summary

Adamis Pharmaceuticals Corporation, formerly Cellegy Pharmaceuticals, Inc., is a specialty pharmaceutical company engaged engages in the research, development, and commercialization of prescription medicines for the treatment of viral infections. Adamis Pharmaceuticals is composed of two wholly owned...

See More

Key Turning Points

2nd Resistance Point 2.43
1st Resistance Point 2.38
Last Price 2.32
1st Support Level 2.26
2nd Support Level 2.19

See More

52-Week High 5.10
Fibonacci 61.8% 3.92
Fibonacci 50% 3.55
Fibonacci 38.2% 3.19
Last Price 2.32
52-Week Low 2.01

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar